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Objectives The aim of this study was to determine whether behavioral mechanisms explain the association between de-
pressive symptoms and myocardial infarction (MI) or death in individuals with coronary heart disease (CHD).
Background Depressive symptoms are associated with increased morbidity and mortality in individuals with CHD, but it is
unclear how much behavioral mechanisms contribute to this association.
Methods The study included 4,676 participants with a history of CHD. Elevated depressive symptoms were defined as
scores 4 on the Center for Epidemiologic Studies Depression 4-item Scale. The primary outcome was definite/
probable MI or death from any cause. Incremental proportional hazards models were constructed by adding de-
mographic data, comorbidities, and medications and then 4 behavioral mechanisms (alcohol use, smoking,
physical inactivity, and medication non-adherence).
Results At baseline, 638 (13.6%) participants had elevated depressive symptoms. Over a median 3.8 years of follow up,
125 of 638 (19.6%) participants with and 657 of 4,038 (16.3%) without elevated depressive symptoms had
events. Higher risk of MI or death was observed for elevated depressive symptoms after adjusting for demo-
graphic data (hazard ratio [HR]: 1.41, 95% confidence interval [CI]: 1.15 to 1.72) but was no longer significant
after adjusting for behavioral mechanisms (HR: 1.14, 95% CI: 0.93 to 1.40). The 4 behavioral mechanisms to-
gether significantly attenuated the risk for MI or death conveyed by elevated depressive symptoms (36.9%,
95% CI: 18.9 to 119.1%), with smoking (17.6%, 95% CI: 6.5% to 56.0%) and physical inactivity
(21.0%, 95% CI: 9.7% to 61.1%) having the biggest explanatory roles.
Conclusions Our findings suggest potential roles for behavioral interventions targeting smoking and physical inactivity in pa-
tients with CHD and comorbid depression. (J Am Coll Cardiol 2013;61:622–30) © 2013 by the American Col-
lege of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.058In recent years, there has been considerable interest in the
negative impact of depression on outcomes among patients
with coronary heart disease (CHD) (1). It is estimated that
approximately 20% of individuals with CHD meet criteria
From the *Center for Behavioral Cardiovascular Health, Department of Medicine,
Columbia University Medical Center, New York, New York; †Department of
Epidemiology, School of Public Health, University of Alabama at Birmingham,
Birmingham, Alabama; and the ‡Department of Medicine, University of Alabama
School of Medicine, Birmingham, Alabama. This research project is supported by a
cooperative agreement U01 NS041588 from the National Institute of Neurological
Disorders and Stroke, National Institutes of Health, Department of Health and
Human Service. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of Neurological
Disorders and Stroke or the National Institutes of Health. Representatives of the
funding agency have been involved in the review of the manuscript but not directlyfor major depression, and up to 40% experience some
depressive symptoms (2,3). Furthermore, the presence of
depression or elevated depressive symptoms in individuals
See page 631
involved in the collection, management, analysis or interpretation of the data. The
authors thank the other investigators, the staff, and the participants of the
REGARDS (REason for Geographic and Racial Differences in Stroke) study for their
valuable contributions. A full list of participating REGARDS investigators and
institutions can be found at http://www.regardsstudy.org. Dr. Ye is supported by an
American College of Cardiology/Merck Research Fellowship award and by National
Institutes of Health Grant T32HL007854-16. Dr. Safford receives salary support
from Amgen, Inc., and Pfizer, Inc., for research studies; she has served as consultant
for DiaDexus. All other authors have reported that they have no relationships relevant
to the contents of this paper to disclose.
Manuscript received September 4, 2012, accepted September 21, 2012.
f
l
h
(
s
p
c
t
c
s
n
t
d
i
l
s
m
e
S
a
n
t
t
f
M
D
p
p
c
t

P
m
m
f
d
J
a
l
d
p
a
t
c
i
R
t
p
D
s
c
p
i
q
s
t
o
s
a
a
v
i
i
h
t
o
w
b
a
s

m
d
h
i
p
t
r
t
f
s
p
a
e
m
m
d
d
a
a
C
t
s
y
i
m
a
o
w
4
h
623JACC Vol. 61, No. 6, 2013 Ye et al.
February 12, 2013:622–30 Behavior Mechanisms, Depression, and MI or Deathwith CHD has consistently been shown to be associated
with a markedly increased risk of adverse events including
death and myocardial infarction (MI) (2–7). Because of this,
national guidelines have recommended screening and treatment of
depression in individuals with CHD (1). However, the evidence
or improving cardiac outcomes by treating depression has been
imited, and trials of interventions to improve depression thus far
ave shown equivocal results with regard to improving cardiac risk
8–10).
A better understanding of mechanisms by which depres-
ion conveys cardiac risk might suggest alternative ap-
roaches for improving outcomes in individuals with con-
omitant depression and CHD. Recent studies have noted
he potential role of behavioral mechanisms that are asso-
iated with both depression and cardiac risk. For instance,
moking (2), physical inactivity (2,11), and medication
on-adherence (12) have all been shown to explain part of
he increased risk for adverse cardiac outcomes conveyed by
epression. However, most studies focused on different
ndividual behavioral mechanisms in selected populations,
imiting their generalizability. In the current study, we
ought to clarify the collective contribution of behavioral
echanisms to the increased cardiac risk conveyed by
levated depressive symptoms in individuals with CHD.
pecifically, we examined the explanatory role played by
lcohol use, smoking, physical inactivity, and medication
on-adherence in the association between depressive symp-
oms and MI or death in participants with CHD enrolled in
he REGARDS (REason for Geographic and Racial Dif-
erences in Stroke) study.
ethods
etails on the REGARDS study have been published
reviously (13). In brief, the REGARDS study is a
opulation-based cohort study of stroke incidence and
ognitive decline with the incidence of CHD being inves-
igated through an ancillary study. The study enrolled adults
45 years of age from the continental United States.
otentially eligible participants were identified from com-
ercially available lists of U.S. residents and sent an initial
ailing that provided details of the study. This mailing was
ollowed by a telephone call and a subsequent in-home visit,
uring which time participants were enrolled. Between
anuary 2003 and October 2007, 30,239 African-American
nd white adults were enrolled. The current analysis was
imited to 5,346 participants with a history of CHD (as
efined in the following text) at baseline. Of these partici-
ants, 26 did not complete depression screening at baseline,
nd 92 were missing follow-up data for outcomes. Addi-
ionally, we excluded 520 participants who were missing
ovariate information. After these exclusions, the analysis
ncluded 4,676 participants with complete data. The
EGARDS study protocol was approved by the institu-
ional review boards at the participating centers, and all
articipants provided informed consent. “ata collection. The REGARDS
tudy baseline data collection in-
luded a computer-assisted tele-
hone interview, an in-home exam-
nation, and self-administered
uestionnaires. Trained research
taff conducted telephone interviews
o collect demographic data and data
n education; income; cigarette
moking; physical activity; aspirin
nd thienopyridine use; and use of antihypertensive, anti-glycemic,
nd cholesterol-lowering medications. During the in-home study
isit, trained and certified health professionals conducted a phys-
cal examination and collected biological samples. Body mass
ndex (BMI) was calculated as weight in kilograms divided by
eight in meters squared. Blood pressure was measured 2
imes following a standardized protocol (14). On the basis
f the average of the 2 blood pressure measurements, hypertension
as defined as systolic blood pressure 140 mm Hg, diastolic
lood pressure 90 mm Hg, and/or self-reported use of
ntihypertensive medication. Diabetes was defined as a
erum glucose 126 mg/dl for participants who had fasted
8 h before their in-home study visit, serum glucose 200
g/dl for those who had not fasted, or self-report of a prior
iagnosis of diabetes with current use of insulin or oral
ypoglycemic medications. A history of MI and stroke were
dentified via self-report. Also, during the in-home visit,
articipants were asked to provide all medications they had
aken in the past 2 weeks, and medication names were
ecorded and subsequently coded into drug classes. During
he in-home examination, an electrocardiogram was per-
ormed. A history of CHD at baseline was defined as a
elf-reported history of MI or coronary revascularization
rocedure (percutaneous coronary intervention or coronary
rtery bypass surgery) or evidence of MI on the study
lectrocardiogram.
For the current analysis, we focused on 4 behavioral
echanisms: alcohol use, smoking, physical inactivity, and
edication non-adherence. On the basis of prior published
ata, light/moderate and heavy alcohol consumption was
efined as consuming 0 to 14 and 15 alcoholic bever-
ges/week, respectively, for men and 0 to 7 and 8
lcoholic beverages/week, respectively, for women (15,16).
urrent smoking was determined by affirmative responses
o both of the following yes/no questions: “Have you
moked at least 100 cigarettes in your lifetime?” and “Do
ou smoke cigarettes now, even occasionally?” Physical
nactivity was assessed through a single question: “How
any times per week do you engage in intense physical
ctivity, enough to work up a sweat?” with response options
f “none,” “1 to 3 times per week,” and “4 or more times per
eek.” Medication non-adherence was assessed with the
-item Morisky Medication Adherence Scale. Each item
as a yes/no response option. One point is assigned to each
Abbreviations
and Acronyms
BMI  body mass index
CHD  coronary heart
disease
CI  confidence interval
HR  hazard ratio
MI  myocardial infarctionyes” response, and points are summed (totaling 0 to 4),
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non-adherence (17,18).
Depressive symptoms. The brief, 4-item Center for Epi-
demiologic Studies Depression Scale was used to assess the
presence of depressive symptoms, by asking how often over
the prior week the participant: 1) felt depressed; 2) felt
lonely; 3) had crying spells, and 4) felt sad, with response
options of 1 day (no points), 1 to 2 days (1 point), 3 to 4
days (2 points), and 5 to 7 days (3 points). Elevated
depressive symptoms were defined as having a summed
score4, which had been reported to have 79.2% sensitivity
and 86.4% specificity for meeting a previously established
threshold for having clinically significant depressive symp-
toms as assessed by the full 20-item Center for Epidemio-
logic Studies Depression Scale (19,20).
Outcomes. The outcomes for the current study included
definite/probable MI or death from any cause. Outcome
data through December 31, 2008 were used in this analysis.
Participants were contacted twice yearly by telephone to
identify potential events, subsequent to the REGARDS
in-home examination. When a cardiac-related hospital stay
was reported, medical records were retrieved and reviewed
by a team of trained physicians with a standardized protocol
(21). Records were examined for the presence of signs or
symptoms suggestive of ischemia, typical rise and fall of
cardiac enzymes, and electrocardiogram changes consistent
with ischemia or MI, guided by the Minnesota code
(22,23). The MIs were adjudicated as being definite, prob-
able, or possible on the basis of published guidelines (22).
For participants who were unable to be contacted for their
bi-annual interviews, an interview was conducted with the next
of kin listed on study forms, and when deaths were reported,
the date of death was confirmed through the Social Security
Death Index, death certificates, or the National Death
Index. Follow-up time was recorded as the number of days
from the baseline in-home visit to confirmed date of death
of participant, occurrence of a definite or probably MI, or
their last REGARDS study telephone contact before De-
cember 31, 2008, whichever occurred first.
Statistical analyses. Characteristics of REGARDS study
articipants with a history of CHD were calculated by
epressive symptom status and compared via t tests and
chi-square tests, as appropriate. With the Kaplan-Meier
approach, the cumulative incidence was calculated for par-
ticipants with and without depressive symptoms, separately,
for: 1) the primary outcome of definite/probable MI or
death; 2) definite/probable MI (fatal or nonfatal); and
3) death from any cause. Next, the hazard ratio (HR) for the
primary outcome associated with depressive symptoms was
calculated in 3 nested models. The first model (Model 1)
included adjustment for demographic data (age, sex, race),
education, income, and BMI. The next model (Model 2)
included additional adjustment for comorbid conditions
(hypertension, diabetes mellitus, self-reported history of
stroke, and self-reported history of MI) and cardiovascular
medication use (aspirin, beta blockers, thienopyridines, cACE-inhibitors/angiotensin receptor blockers, statins, and
antidepressants). The final model (Model 3) included addi-
tional adjustment for behavioral mechanisms, including
alcohol use, cigarette smoking, physical inactivity, and
medication non-adherence. For physical activity, because
those who reported “1 to 3 times per week” and “4 or more
times per week” had similar HRs as compared with the
reference group of those who reported “none,” the final
model considered physical activity as a dichotomous vari-
able, where participants who answered “none” were classi-
fied as physically inactive. We also repeated, as a sensitivity
analysis, the aforementioned analysis after excluding prob-
able MI (fatal or nonfatal) from the outcome.
To quantify the amount of association between elevated
depressive symptoms and CHD risk that is explained by
behavioral risk factors (24), we used the bootstrap method
recommended by Preacher and Hayes (25,26). Specifically,
with the model that included age, sex, race, education,
income, and BMI, the percentage of the association be-
tween depressive symptoms and the primary outcome ex-
plained by comorbidities, medication use, and behavioral
mechanisms was calculated. To do so, we used a 1,000-
iteration bootstrap; each iteration included 4,676 observa-
tions chosen at random from the original dataset with
replacement. For each iteration, we modeled the primary
outcome with and without adjustment for the explanatory
variables (after and before, respectively) and calculated the
ercentage change in the beta coefficient between the 2
odels ([after  before]/before). The median difference
as used as the percentage attenuation with the 2.5th and
7.5th percentiles as empirical 95% confidence intervals
CIs). Analyses were conducted with SAS version 9.2 (SAS
nstitute, Cary, North Carolina).
esults
aseline characteristics. Of 4,676 REGARDS partici-
ants included for analysis, 638 (13.6%) had elevated
epressive symptoms. Compared with 4,038 (86.4%) par-
icipants without elevated depressive symptoms, those with
levated depressive symptoms were younger, less likely to be
ale, more likely to be black, less likely to have graduated
rom high school, more likely to have annual income
$20,000, and more likely to have higher BMI (Table 1).
articipants with depressive symptoms were more likely to
ave hypertension, diabetes mellitus, and a self-reported
istory of stroke. Participants with depressive symptoms
ere also more likely to be taking thienopyridines and
ntidepressants and less likely to be taking statins at
aseline.
For behavioral mechanisms, participants with elevated
epressive symptoms were more likely to report no alcohol
se and less likely to report either light-to-moderate or
eavy alcohol use (p 0.001 for overall comparison). Those
ith elevated depressive symptoms were more likely to beurrent smokers (27.6% vs. 13.8%; p  0.001) and to report
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February 12, 2013:622–30 Behavior Mechanisms, Depression, and MI or Deathphysical inactivity (51.9% vs. 36.1%; p  0.001). Partici-
ants with elevated depressive symptoms reported worse
evels of medication adherence (Morisky scale score of 3 or
, 5.8% vs. 2.3%; p  0.001).
linical events, elevated depressive symptoms, and
ehavioral mechanisms. Over a median 3.8 years of follow
p, 125 (19.6%) of 638 participants with elevated depressive
ymptoms experienced the primary outcome of definite/
robable MI or death, compared with 657 (16.3%) of 4,038
articipants without (Fig. 1, top panel). After adjusting for
emographic data, education, income, and BMI (Table 2,
odel 1), the HR for MI or death associated with depres-
ive symptoms was 1.41 (95% CI: 1.15 to 1.72). After
urther adjustment for medical comorbidities and medica-
ions used (Table 2, Model 2), the HR remained statistically
ignificant but decreased to 1.25 (95% CI: 1.02 to 1.52).
inally, in the full model including all 4 behavioral mech-
Baseline Characteristics of Participants With CTable 1 Baseline Characteristics of Particip
No E
Symp
Demographic data
Age, mean (SD), yrs
Male
Black
High school graduate
Income $20,000
BMI, mean (SD)
Comorbidities
Hypertension
MI*
Stroke*
Diabetes mellitus
Medication use
Aspirin
Beta blocker
Thienopyridine
Ace-inhibitor/angiotensin receptor blocker
Statin
Antidepressants
Behavioral risk factors
Alcohol use
None
Light-to-moderate
High
Current smoking
Physical inactivity
None
1 times/week
Morisky scale for medication non-adherence
0 (best adherence)
1
2
3 or 4 (worst adherence)
By elevated depressive symptoms (Center for Epidemiologic Studies D
of myocardial infarction (MI) and stroke as identified by self-report.
BMI  body mass index.nisms (Table 2, Model 2), the HR for MI or deathassociated with elevated depressive symptoms was further
attenuated and was no longer statistically significant (HR:
1.14, 95% CI: 0.93 to 1.40). For individual behavioral
mechanisms, both smoking (HR: 2.06, 95% CI: 1.71 to
2.47) and physical inactivity (HR: 1.47, 95% CI: 1.27 to
1.71) were associated with a higher risk of MI or death in
the fully adjusted model (Table 2, Model 3), whereas levels
of alcohol use and medication non-adherence were not.
Only 14.0% (95% CI: 2.5% to 44.3%) of the excess
risk for MI or death associated with elevated depressive
symptoms was due to medical comorbidities including
hypertension, history of MI, history of stroke, and diabetes
mellitus (Table 3). Medication use did not significantly
attenuate the HR for elevated depressive symptoms (HR:
27.4%, 95% CI: 12.7% to 86.1%). In contrast, inclusion
of all 4 behavioral mechanisms into the model attenuated
more than one-third of the risk for MI or death associated
ry Heart DiseaseWith Coronary Heart Disease
d Depressive
(n  4,038)
Elevated Depressive
Symptoms (n  638) p Value
 8.8 65.5 9.5 0.001
3.1 43.3 0.001
2.5 49.2 0.001
5.3 71.3 0.001
0.8 47.0 0.001
 5.8 30.7 6.8 0.001
1.3 80.1 0.001
1.4 73.5 0.260
1.2 17.1 0.001
1.8 41.5 0.001
0.2 67.1 0.110
7.1 50.9 0.073
5.1 18.8 0.015
0.5 52.4 0.384
9.6 51.3 0.001
3.0 30.9 0.001
3.7 73.7 0.001
3.2 23.5
3.1 2.8
3.8 27.6 0.001
6.1 51.9 0.001
3.9 48.1
9.0 58.8 0.001
4.3 26.7
4.4 8.7
2.3 5.8
on Scale score4). Values are % except otherwise specified. *Historyoronaants
levate
toms
68.9
6
3
8
2
29.2
7
7
1
3
7
4
1
5
5
1
6
3
1
3
6
6
2
epressiwith elevated depressive symptoms (HR: 36.9%, 95% CI:
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having the biggest impact (Table 3).
Individual outcomes and sensitivity analyses. As a sec-
ondary analysis, we further explored the role of behavioral
mechanisms in explaining the association between elevated
depressive symptoms and the individual components of the
primary outcome (definite/probable MI and all-cause mor-
tality, separately), with the same incremental proportional
hazards models specified in the preceding text. During the
follow-up period, 101 (15.8%) of 638 participants with
Figure 1 Kaplan-Meier Curves for Adverse Events
Cumulative incidence of definite/probable myocardial infarction (MI) or death;
definite/probable MI (fatal or nonfatal); or death from any cause, for REGARDS
(REason for Geographic and Racial Differences in Stroke) participants with and
without elevated depressive symptoms.elevated depressive symptoms died, compared with 504(12.5%) of 4,038 participants without elevated depressive
symptoms; 50 (7.8%) of 638 participants with elevated
depressive symptoms and 314 of (7.8%) 4,038 participants
without experienced a definite/probable MI (Fig. 1, middle
and bottom panels). The results of proportional hazards
models for death were consistent with the findings from the
primary analyses: the HR for elevated depressive symptoms
was 1.48 (95% CI: 1.18 to 1.85) in the model containing
demographic covariates and BMI only but was no longer
statistically significant (HR: 1.20, 95% CI: 0.96 to 1.50) in
the fully adjusted model containing behavioral mechanisms.
For definite/probable MI, a similar trend was observed,
although none of the HRs met statistical significance (Fig. 2). In
sensitivity analysis excluding probable MI events, the find-
ings were similar.
Discussion
In this analysis of a large cohort of participants from across
the continental United States enrolled in the REGARDS
study, we found that self-reported behavioral mechanisms
explained a substantial proportion of the excess risk of MI or
death associated with elevated depressive symptoms in
individuals with CHD. Of the 4 behavioral mechanisms
that were assessed, smoking and physical inactivity were the
most substantial contributors, each accounting for approx-
imately one-fifth of the relationship between elevated de-
pressive symptoms and cardiac risk. We also confirmed that
elevated depressive symptoms are associated with an in-
creased risk of MI or death in individuals with CHD, a
relationship that was mainly driven by the increased risk of
death.
Our results are consistent with and extend the findings of
prior studies in this field (2,11). In an analysis of 5,888
participants enrolled in the Cardiovascular Health Study,
Win et al. (11) reported that physical inactivity accounted
for 25% of the increased risk for cardiovascular mortality
associated with depression. We observed an effect size of a
similar magnitude for physical inactivity in our cohort but
also considered other behavioral mechanisms, such as smok-
ing, alcohol use, or medication non-adherence, which were
not accounted for in the Cardiovascular Health Study. Our
results are also similar to that from the Heart and Soul
Study, which found that self-reported physical inactivity
explained approximately 30% and smoking approximately
10% of the association between depressive symptoms and
increased cardiovascular events, whereas the contribution of
medication non-adherence was similarly of borderline sig-
nificance as observed in our cohort (2). The prevalence of
elevated depressive symptoms was slightly lower in our
cohort (13.6%), compared with these prior studies, which
might be due to our study sample being population-based as
well as our use of a different measure and threshold for
defining elevated depressive symptoms. However, our larger
sample size and the robust bootstrapping method we used
go further to support the role of smoking and physical
r blocke
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February 12, 2013:622–30 Behavior Mechanisms, Depression, and MI or Deathinactivity as key behavioral mechanisms that explain the
association between elevated depressive symptoms and the
risk of MI or death.
In our study, alcohol use and medication non-adherence
did not attenuate the relationship between elevated depres-
sive symptoms and MI or death. There are several potential
explanations. The precise impact of alcohol consumption on
cardiovascular risk remains under debate (16,27), and it has
been proposed that physical activity might be a confounder
for epidemiological observations that link light-to-moderate
alcohol use with decreased number of cardiac events (28).
Supporting this, alcohol consumption was not associated
with MI or death in the full model that included physical
activity in our study and thus would not be expected to
explain the association between elevated depressive symp-
toms and cardiac outcomes. For medication non-adherence,
although we used the 4-item Morisky scale rather than a
single-item assessment as was done in the Heart and Soul
Study, underreporting of medication non-adherence is a
Association Between Elevated DepressiveSymptoms and Definite/Probable MI or DeathTable 2 Association Between El vat d DepSymptoms and Definite/Probable M
Mod
HR (9
Elevated depressive symptoms 1.41 (1.1
Age, per 10 yrs 1.52 (1.3
Male 1.44 (1.2
Black 1.11 (0.9
High school graduate 0.87 (0.7
Annual household Income $20K 1.53 (1.2
BMI, per 5 kg/m2 0.94 (0.8
Hypertension
MI†
Stroke†
Diabetes mellitus
Aspirin
Beta blocker
Thienopyridine
ACE-inhibitor/ARB
Statin
Antidepressant use
Alcohol use
None
Light-to-moderate
High
Current smoking
Physical activity
Any
None
Morisky scale for medication adherence
0 (best adherence)
1
2
3 or 4 (worst adherence)
Association between elevated depressive symptoms (Center for Epidem
myocardial infarction (MI) or death. Models also included adjustment fo
of MI and stroke as identified by self-report.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptoknown challenge for assessments based on self-report (29).It is possible that more objective measurement tools would
demonstrate a more important role for medication non-
adherence. Consistent with this, a study of 168 patients
with acute coronary syndrome has previously shown that
aspirin non-adherence measured with electronic pill-bottles
accounted for a substantial amount of the risk for increased
death or major adverse cardiovascular events associated with
elevated depressive symptoms (12).
In our analysis, we found that the association of elevated
depressive symptoms with death was significant, whereas
that between elevated depressive symptoms and MI was not.
A similarly nonsignificant association between elevated
depressive symptoms and MI was also seen in the Heart and
Soul Study, which also showed that the relationship be-
tween elevated depressive symptoms and other cardiovascu-
lar events such as stroke and heart failure was more
pronounced (2). A meta-analysis by van Melle et al. (30)
noted a stronger link between depression and death in
post-MI patients than that between depression and cardio-
e
Death
Model 2
HR (95% CI)
Model 3
HR (95% CI)
2) 1.25 (1.02–1.52) 1.14 (0.93–1.40)
5) 1.53 (1.40–1.67) 1.64 (1.50–1.80)
9) 1.46 (1.24–1.72) 1.54 (1.31–1.82)
0) 1.00 (0.85–1.18) 0.97 (0.82–1.14)
5) 0.94 (0.78–1.13) 0.97 (0.80–1.16)
3) 1.45 (1.21–1.73) 1.30 (1.09–1.56)
1) 0.89 (0.83–0.95) 0.91 (0.84–0.97)
1.20 (0.99–1.43) 1.21 (1.01–1.44)
1.35 (1.14–1.60) 1.31 (1.11–1.55)
1.43 (1.19–1.72) 1.34 (1.11–1.61)
1.58 (1.35–1.84) 1.55 (1.33–1.80)
0.90 (0.77–1.05) 0.89 (0.76–1.05)
1.18 (1.02–1.37) 1.18 (1.02–1.36)
1.36 (1.13–1.64) 1.35 (1.12–1.63)
1.04 (0.89–1.21) 1.05 (0.90–1.22)
0.73 (0.63–0.85) 0.75 (0.64–0.87)
1.29 (1.07–1.56) 1.20 (0.99–1.45)
*
1.00 (ref)
0.93 (0.79–1.09)
0.69 (0.43–1.11)
* 2.06 (1.71–2.47)
*
1.00 (ref)
1.47 (1.27–1.71)
*
1.00 (ref)
1.15 (0.97–1.35)
1.23 (0.90–1.67)
0.80 (0.51–1.25)
Studies Depression Scale score of4 vs.4) and definite/probable
aphic region of residence. *Not included in regressionmodel. †History
r; BMI  body mass index.ressiv
I or
el 1
5% CI)
5–1.7
9–1.6
2–1.6
4–1.3
3–1.0
8–1.8
8–1.0
*
*
*
*
*
*
*
*
*
*
*
*
*
iologic
r geogrvascular events including recurrent MI. Therefore, there is a
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the risk for death through causes other than recurrent
myocardial infarction, potentially via mechanisms for which
smoking and physical inactivity are contributors (3,31).
Our study also has, in addition to these mechanistic
insights, important implications for future research and
potential interventions for patients with CHD and elevated
depressive symptoms. Given that prior studies of pharma-
cological and counseling approaches of depression treatment
demonstrated only limited efficacy in reducing cardiac risk
in that patient population (8–10), our results suggest that
there might be a role for intermediary interventions that
explicitly target health behaviors. Despite clear guidelines,
many individuals with CHD and especially those with
depressive symptoms still do not meet current recommen-
dations for smoking cessation and exercise (32). The re-
cently published UPBEAT (Understanding the Prognostic
Figure 2 HRs for Elevated Depressive Symptoms in Incrementa
Hazard ratios (HRs) for elevated depressive symptoms in incremental proportional
dial infarction (MI) (fatal or nonfatal); or the composite of both endpoints. Model 1
adjusted for all covariates in Model 1, with additional adjustment for comorbidities
adjustment for behavioral mechanisms (alcohol use, current smoking, physical ina
Attenuation in Association Between ElevatedDepressive Symptoms and D finit /Prob ble MIor Death, After Addit on f Clinical andB havioral Variables
Table 3
Attenuation in Association Between Elevated
Depressive Symptoms and Definite/Probable MI
or Death, After Addition of Clinical and
Behavioral Variables
% Attenuation
HR (95% CI)
Hypertension/MI/stroke/ diabetes mellitus 14.0% (2.5% to44.3%)
Medications (aspirin, beta blockers, ACE-I/ARBs,
thienopyridine, statins, antidepressants)
27.4% (12.7% to 86.1%)
Alcohol use 0% (4.8% to 3.0%)
Current smoking 17.6% (6.5% to56.0%)
Physical inactivity 21.0% (9.7% to61.1%)
Medication non-adherence 3.6% (2.5% to16.1%)
All behavioral mechanisms 36.9% (18.9% to 119.1%)
Attenuation in the association between elevated depressive symptoms (Center for Epidemiologic
Studies Depression Scale of4 vs.4) and definite/probable MI or death, after addition of clinical
and behavioral variables. Baseline model is Model 1 in Table 3 and includes adjustment for age,
race, sex, geographic region of residence, income, education, and BMI.
Abbreviations as in Table 2.Benefits of Exercise and Antidepressant Therapy) trial
demonstrated that a 4-month exercise intervention was able
to reduce depressive symptoms in patients with CHD, but
the trial was not powered to find differences in cardiac
outcomes (33). Given our findings that behavioral risk
factors explain a substantial part of the association between
elevated depressive symptoms and the risk of MI or death,
future trials of interventions targeting these particular be-
haviors to improve cardiac outcomes in patients with CHD
and elevated depressive symptoms are urgently needed.
There are several strengths in our study. The REGARDS
study includes a large number of women and African
Americans and recruited adults from across the continental
United States, supporting the generalizability of our find-
ings. Furthermore, we used the statistical approach of
bootstrapping to quantify the amount of attenuation of the
relationship between elevated depressive symptoms and
the risk of MI or death after behavioral mechanisms were
considered, which allowed us greater confidence in the
robustness of our results. Finally, although we used brief,
self-reported items to measure behavioral mechanisms and
depressive symptoms at a single point in time, their ease-
of-use and positive associations with outcomes suggest a
potential role for broader application in clinical and research
settings.
Study limitations. As stated in the preceding text, the
measures of behavioral risk factors including smoking,
physical inactivity, alcohol use, and medication non-
adherence in our study were self-reported, and their exact
prevalence might be underestimated. The REGARDS
study did not assess other potential biological factors, such
as endothelial dysfunction and heart rate variability, which
have been proposed to explain the association between
depressive symptoms and cardiac risk (1,34). Prior studies,
portional Hazard Models
d models, with the outcomes of death from any cause; definite/probable myocar-
sted for demographic data, education, income and body mass index. Model 2:
edication use. Model 3: adjusted for all covariates in Model 2, with additional
and medication non-adherence).l Pro
hazar
: adju
and m
ctivity,
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mechanisms might be modest (2,7,35,36). It is also possible
that there is a survivor bias, because those individuals with
elevated depressive symptoms and who are at the highest
risk for death would not have survived to be enrolled in our
study. However, this would tend to bias our results toward
the null and thus would only underestimate the associations
that we have identified between elevated depressive symp-
toms, clinical events, and behavioral mechanisms. Finally,
causality cannot be ascertained in our observational study.
For instance, it is possible that physical inactivity and
depressive symptoms are both markers of disease severity
rather than causal determinants of cardiac risk. Future
studies, possibly with a cross-lagged path design (37), might
help to clarify the complex relationships between depressive
symptoms, cardiac risk, and behavioral mechanisms such as
physical inactivity and smoking.
Conclusions
In summary, we found that in a large cohort of participants
from across the continental United States enrolled in the
REGARDS study, elevated depressive symptoms are asso-
ciated with increased risk of MI or death in individuals with
a history of CHD. Furthermore, a substantial proportion of
the relationship between elevated depressive symptoms and
the risk for MI or death was explained by behavioral
mechanisms, the most important of which were smoking
and physical inactivity. These findings add to our under-
standing of the mechanisms by which elevated depressive
symptoms might convey increased risk for adverse cardio-
vascular outcomes for individuals with CHD and suggest
that behavioral interventions to target smoking cessation
and increase physical activity could reduce the excessive
cardiac risk associated with depression in CHD patients.
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